本文已被：浏览 653次 下载 426次
Received:May 27, 2022 Published Online:November 20, 2022
Received:May 27, 2022 Published Online:November 20, 2022
中文摘要: 肝细胞癌(HCC)是全球范围内致死率最高的恶性肿瘤之一，其发生发展与病毒性肝炎及肝纤维化/肝硬化密不可分。在HCC的发生发展过程中，新型免疫检查点TIGIT/CD155发挥着免疫抑制作用，导致机体免疫失调。本文对TIGIT/CD155的功能及其在HCC发生发展中的作用机制作一综述，以期探究该免疫检查点在HCC免疫治疗中的应用前景。
Abstract:Hepatocellular carcinoma (HCC) is one of the most lethal malignant tumors in the world. Its occurrence and development are closely related to viral hepatitis and liver fibrosis/cirrhosis. During the occurrence and development of HCC, TIGIT/CD155, a new immune checkpoint, plays an immunosuppressive role, leading to immune imbalance. This paper reviews the function of TIGIT/CD155 and its mechanism in the occurrence and development of HCC, to explore the application prospect of TIGIT/CD155 in HCC immunotherapy.
keywords: TIGIT CD155 Immune checkpoint Hepatocellular carcinoma Immunotherapy Viral hepatitis Hepatic fibrosis Liver cirrhosis
文章编号： 中图分类号： 文献标志码：A
基金项目:辽宁省自然科学基金项目（20180551193，2020-MS-181）；盛京医院345人才工程计（40B）
| Author Name | Affiliation |
| WANG Jun-qi, XU Feng | Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China |
| Author Name | Affiliation |
| WANG Jun-qi, XU Feng | Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China |
引用文本：